Form 4: Eledon Pharmaceuticals CEO Receives Stock Grant
Insider Transaction (Form 4)
David-Alexandre C Gros, Chief Executive Officer and a Director of Eledon Pharmaceuticals, Inc., reported multiple transactions in common stock on July 31, 2026.
Summary
- Grant/award: acquired 354,454 Common Stock on July 31, 2026; holds 363,454 after (Direct).
- Tax/exercise-price withholding: disposed of 194,791 Common Stock at $3.38 ($658,394) on July 31, 2026; holds 168,663 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
David-Alexandre C Gros — Director, Officer (Chief Executive Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-31 | Grant/award | Common Stock | 354,454 | — | — | 363,454 |
| 2026-07-31 | Tax/exercise-price withholding | Common Stock | 194,791 | $3 | $658.4K | 168,663 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-31 | Grant/award (354,454 shares) |
| 2026-07-31 | Tax/exercise-price withholding (194,791 shares) |
Keywords
insider transaction, Form 4, ELDN, Eledon Pharmaceuticals, Inc., neutral, David-Alexandre C Gros
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.